Wide Ranks

CNTA

Centessa Pharmaceuticals plc

17.60

Top Statistics
Market Cap 2 B Forward PE -11.31 Revenue Growth 0.00 %
Current Ratio 0.00 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -9.94 Enterprise / Revenue 233.96 Price To Sales Trailing12 Months 338.61
Profitability
Profit Margins 0.00 % Operating Margins -2358.87 %
Balance Sheet
Total Cash 518 M Total Cash Per Share 4.46 Total Debt 75 M
Total Debt To Equity 15.17 Current Ratio 0.00 Book Value Per Share 4.29
All Measures
Short Ratio 559.00 % Message Board Id finmb_704505677 Shares Short Prior Month 2 M
Return On Equity -0.4252 City Altrincham Uuid 9f3bdf1d-ddc8-3bbd-88f7-8fed1cc82ba8
Previous Close 17.30 First Trade Date Epoch Utc 1 B Book Value 4.29
Total Debt 75 M Volume 510301 Price To Book 4.10
Fifty Two Week Low 5.58 Total Cash Per Share 4.46 Total Revenue 6 M
Shares Short Previous Month Date 1 B Target Median Price 27.00 Max Age 86400
Recommendation Mean 1.25 Sand P52 Week Change 0.3133 Operating Margins -2358.87 %
Target Mean Price 28.57 Net Income To Common -161264992 Short Percent Of Float 0.0227
Implied Shares Outstanding 131 M Trailing Peg Ratio None Last Fiscal Year End 1 B
Average Daily Volume10 Day 733850 Average Volume10days 733850 Total Cash 518 M
Next Fiscal Year End 1 B Revenue Per Share 0.0650 Held Percent Insiders 0.0132
Trailing PE 0.0000 Date Short Interest 1 B Most Recent Quarter 1 B
Regular Market Previous Close 17.30 Target Low Price 24.00 Gmt Off Set Milliseconds -18000000
Fifty Day Average 16.16 Open 17.30 Dividend Yield 0.00 %
Return On Assets -0.2047 Time Zone Short Name EST Trailing Eps -1.52
Day Low 17.30 Address1 1 Ashley Road Shares Outstanding 131 M
Price Hint 2 Target High Price 35.00 Website https://www.centessa.com
52 Week Change 1.93 Average Volume 671956 Forward Eps -1.71
Recommendation Key strong_buy Compensation As Of Epoch Date 1 B Is_sp_500 False
Regular Market Day High 17.66 Profit Margins 0.00 % Debt To Equity 15.17
Fifty Two Week High 18.74 Day High 17.66 Shares Short 2 M
Regular Market Open 17.30 Industry Key biotechnology Earnings Growth 0.00 %
Enterprise To Revenue 233.96 Revenue Growth 0.00 % Shares Percent Shares Out 0.0185
Currency USD Time Zone Full Name America/New_York Market Cap 2 B
Is_nasdaq_100 False Zip WA14 2DT Quote Type EQUITY
Industry Biotechnology Long Name Centessa Pharmaceuticals plc Regular Market Day Low 17.30
Held Percent Institutions 0.9252 Current Price 17.60 Address2 3rd Floor
Enterprise To Ebitda -9.94 Financial Currency USD Current Ratio 0.00
Gross Margins 100.00 % Industry Disp Biotechnology Number Of Analyst Opinions 7
Country United Kingdom Float Shares 78 M Two Hundred Day Average 12.02
Enterprise Value 1 B Price To Sales Trailing12 Months 338.61 Forward PE -11.31
Regular Market Volume 510301 Ebitda -161299008 Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients.

Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.

The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy.

In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs.

Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.